ClinicalTrials.Veeva

Menu

Open-label Extension Study Of RN624

Pfizer logo

Pfizer

Status and phase

Completed
Phase 2

Conditions

Osteoarthritis
OA Knee Pain
Arthritis

Treatments

Drug: RN624 (PF-04383119)

Study type

Interventional

Funder types

Industry

Identifiers

NCT00399490
RN624-CL007 (Other Identifier)
A4091009

Details and patient eligibility

About

Study RN624-CL007 is planned to be an open-label protocol to enroll subjects who have previously participated in Study No. RN624-CL006. In this study, subjects will receive RN624 on an open-label basis.

Enrollment

287 patients

Sex

All

Ages

40 to 75 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Enrolled in Study RN624-CL006

Exclusion criteria

  • The occurrence of any adverse event or condition during the controlled studies that, in the opinion of the Investigator, should exclude the subject from participating in the open-label extension
  • Pregnant or lactating female subjects or subjects who do not agree to use an appropriate form of birth control throughout the study and for 3 months after completing the study

Trial design

Primary purpose

Treatment

Allocation

Non-Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

287 participants in 1 patient group

1
Experimental group
Treatment:
Drug: RN624 (PF-04383119)

Trial contacts and locations

36

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems